FDA cuts off use of GSK's Covid treatment in almost half of the US as BA.2 spreads

With the rise of the Omicron sister variant BA.2, GlaxoSmithKline and Vir Biotechnology’s crucial monoclonal antibody — one of only two mAbs still being shipped by the US government to states to treat Covid-19 — has finally met its match, and almost half of all US states have now lost access to the crucial mAb as it’s not as effective against the new strain.